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Previews
the -lactamase chain into MBP [7]. In principle, thisEngineering Switches, Genetically
library contains a series of new proteins that have
-lactamase inserted into MBP at every position in the
MBP chain. However, because the nonhomologous re-
Ostermeier, Guntas, and Mitchel describe a new ap- combination protocol relies on DNAase treatment, MBP
proach to design enzymes that are allosterically regu- sequences near the insert site typically contain either
lated by an unrelated ligand [1]. The resulting protein, deletions or insertions. This rough “cut and paste” li-
constructed by nonhomologous recombination and brary makes it necessary to perform genetic screens
genetic screens, displays switch-like behavior. that identify fusion proteins that bear both activities. In
their first attempt, this approach resulted in two
Naturally occurring proteins currently represent the -lactamases that vary kcat/Km by 1.7- to 1.8-fold in the
best examples of soft (molecularly compliant) nanoscale presence of an MBP ligand.
devices. These devices can sometimes behave as To do better, the authors had to realize that there
were probably better sites within -lactamase than theswitches, modulating their principle catalytic or binding
N and C terminus on which to pull and tug and therebyactivity based upon the action of a second binding part-
change its activity. This is where circular permutationner. The advent of large-scale sequencing efforts has
comes into play. Circular permutation is the process ofdramatically increased the number of known proteins,
creating a series of linear molecules that would resultproviding a potentially vast parts store that can be scav-
if the chain were cyclized end to end and then reopenedenged to create fundamentally new activities. While
somewhere else in the chain. This idea can be appliedthere is great interest among a new breed of molecular
generally to biomolecules be they DNA [8], RNA [9], orhot rodders to raid this databank, the challenge ahead
proteins [10]. In many proteins (such as -lactamase),lies in putting parts together effectively, because cou-
designing a series of circular permutations is straightfor-pling the activity of two proteins is somewhat more diffi-
ward because the N and C terminus are close in spacecult than putting a new carburetor on your car.
and can be joined by a short linker peptide.In this issue of Chemistry & Biology, Guntas et al., [1]
The Ostermeier group created a library of-lactamaseprovide an elegant example of how circular permutation,
circular permutations by joining the N and C terminusnonhomologous recombination, and genetic screens
with a flexible peptide linker and then opening the chaincan be combined to purposefully create a novel type of
randomly at internal positions (see Figure 1 in the ac-protein-based switch. Conceptually, the idea is straight-
companying paper [1]). They then inserted this libraryforward, take an enzyme (here -lactamase) and make
into MBP via nonhomologous recombination as beforeits activity dependent upon the binding of an unrelated
and screened the resulting variants. Statistically, theyligand such as maltose. To do this, the authors chose
determined that the resulting library started with moreto create a fusion protein that had both -lactamase
than 27,000 MBP--lactamase fusion proteins. Afterand maltose binding protein (MBP) domains in the same
screening, they performed detailed kinetic analysis ofchain. Maltose binding protein seemed a particularly
the best variant (termed RG13), demonstrating that thisattractive regulatory domain because it is known to un-
protein has25-fold swing in activity based on the pres-dergo a significant conformational change upon binding
ence or absence of maltose.the ligand [2].
What lessons can we take from this study? First, that
The design challenge they faced was determining how
allosterically regulated enzymes (switches) can be cre-
to put these two proteins together in a way that couples
ated via recombination and genetic means. In funda-
their activities. This is a problem that has been ap- mentally soft materials like proteins, context and confor-
proached by other labs in making sensors or altering mation matter and are usually coupled together in a
modular signal transduction pathways. For example, complicated way with the primary sequence [11]. Engi-
various FRET-based sensors have been designed by neering through genetics provides a powerful opera-
tethering the fluorescent dye pair CFP and YFP using a tional approach that enables solving a design problem
domain that undergoes a conformational change upon without explicitly understanding all the underlying vari-
action by a cellular protein [3–5]. Similarly, Lim and co- ables.
workers have shown that novel scaffold-based signaling This operational approach may seem less satisfying
cascades can be engineered by assembly of fusion pro- than computational design methods set out to accom-
teins from a series of recognition domains that undergo plish the same phenomenon [12, 13]. However, genetic
conformational changes upon seeing some signal [6]. and computational design approaches are more similar
In these cases, tethering the pieces together is sufficient than they are different. In silico, many different designs
to create the intended switch. are tested and sieved by combining energetic calcula-
Ostermeier and coworkers faced a more challenging tions and search-limiting algorithms in an effort to iden-
problem because their fusion protein switch needed to tify the most “fit.” In this view, computational protein
be engineered such that ligand-dependent conforma- designers may be seen as electronic geneticists.
tional changes (pulling, pushing, moving about) in MBP The newly designed molecule reported here repre-
altered the activity of the enzymatic domain. In their sents an important proof-of-principle and is potentially
previous work, the Ostermeier group created a series useful both for its intended purpose (i.e., as a switch) and
also to provide a methodology for linking the function ofof new proteins by nonhomologous recombination of
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lar events may underly the pathogenesis of the differentTargeting -Synuclein
“protein aggregation” diseases.in Parkinson’s Disease Parkinson’s disease is the most common human neu-
rodegenerative movement disorder and affects 1% of
the elderly population. Although symptomatic treatment
strategies are available, PD has remained a noncurable
disease [5]. Primary clinical symptoms of PD are brady--Synuclein aggregation into fibrils is associated with
kinesia, resting tremor, muscular rigidity, and difficultythe pathogenesis of Parkinson’s disease (PD). Li et al.
with balance. PD is neuropathologically characterizedprovide strong evidence that rifampicin interacts with
by a marked and progressive degeneration of dopami--synuclein and inhibits its fibrillization [1]. Rifampicin
nergic neurons and by the presence of fibrillar cyto-could be a promising candidate for therapeutic appli-
plasmatic inclusions (Lewy bodies [LBs]) and dystrophiccation for PD.
neurites (Lewy neurites [LNs]) in the substantia nigra
region of the brain [6]. Although the loss of dopamine
Sometimes an observation may produce a hypothetical neurons is certainly related to the major clinical symp-
link between two apparently unrelated events. For ex- toms of PD, the causes and the pathogenesis of this
ample, the observation by McGeer et al. and Namba et multifactorial disease as well as that of related “synuclei-
al. that anti-leprosy-treated elderly patients have less nopathies” are still largely unknown.
dementia and senile plaques in their brains than non- The major components of both LBs and LNs are fibril-
treated patients has created a link between the anti- lar aggregates of -synuclein [6, 7]. -Synuclein is a
leprosy drug rifampicin and neurodegenerative diseases widely expressed, neuronal presynaptic protein that ap-
[2, 3]. How this hypothesis has been pursued and what pears to play a role in membrane-associated processes
might be the potential consequences for PD and other and synaptic plasticity and has been linked to learning
cell-degenerative diseases will be discussed here. and development processes [6]. While the mechanism(s)
In vivo protein aggregation into fibrillar deposits is of formation of LBs and LNs and their association with
strongly associated with cell degeneration and the PD is (are) yet not understood, several lines of evidence
pathogenesis of a number of progressive cell-degenera- suggest that -synuclein fibrillization is associated with
tive diseases. These include fatal neurodegenerative PD [6, 8]. Similarily to other protein aggregation dis-
diseases such as Alzheimer’s disease (AD), Parkinson’s eases, both neurotoxic and neuroprotective roles have
disease (PD), Huntington’s disease (HD), the transmissa- been attributed to the endproducts of -synuclein
ble spongiform encephalopathies (TSEs or prion dis- aggregation, the fibrillar -synuclein deposits [6, 8].
eases), the pancreatic  cell degenerative disease type -Synuclein fibril formation in vitro proceeds via the
II diabetes (T2D), and several other localized or systemic conversion of the 140 amino acid residue protein, that
amyloidoses [4]. In all these conditions, a disease-spe- appears to be “natively unfolded,” into ordered,  sheet-
cific polypeptide or protein aggregates into fibrillar de- rich oligomers also termed “protofibrils” [8]. -Synuclein
protofibrils or alternatively folded/assembled oligomersposits. Recent evidence suggests that common molecu-
